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ABSTRACT 
Tissue inhibitor of metalloproteinases 3 (TIMP-3) is a key regulator of extracellular matrix 
turnover for its ability to inhibit matrix metalloproteinases (MMPs), adamalysin-like 
metalloproteinases (ADAMs) and ADAMs with thrombospondin motifs (ADAMTSs). TIMP-3 
is a secreted protein whose extracellular levels are regulated by endocytosis via the low-
density-lipoprotein receptor-related protein-1 (LRP-1). In this study we developed a molecule 
able to “trap” TIMP-3 extracellularly, thereby increasing its tissue bioavailability. LRP-1 
contains four ligand-binding clusters. In order to investigate the TIMP-3 binding site on LRP-
1, we generated soluble minireceptors (sLRPs) containing the four distinct binding clusters 
or part of each cluster. We used an array of biochemical methods to investigate the binding 
of TIMP-3 to different sLRPs. We found that TIMP-3 binds to the ligand-binding cluster II of 
the receptor with the highest affinity and a soluble minireceptor containing the N-terminal 
half of cluster II specifically blocked TIMP-3 internalization, without affecting the turnover of 
metalloproteinases. Mass spectrometry-based secretome analysis showed that this 
minireceptor, named T3TRAP, selectively increased TIMP-3 levels in the extracellular space 
and inhibited constitutive shedding of a number of cell surface proteins. In conclusion, 
T3TRAP represents a biological tool that can be used to modulate TIMP-3 levels in the 
tissue and could be potentially developed as a therapy for diseases characterized by a 
deficit of TIMP-3, including arthritis. 
 
1. INTRODUCTION 
The timely degradation of 
extracellular matrix (ECM) components is 
crucial for several biological processes, 
including cell migration, development and 
tissue repair (1). ECM turnover involves the 
activity of different classes of proteinases, 
with the matrix metalloproteinases (MMPs) 
and adamalysin-like metalloproteinases 
with thrombospondin domains (ADAMTSs) 
playing a leading role among them. The 
related family of membrane-anchored 
adamalysins (ADAMs) proteolytically cleave 
proteins at the cell surface, thereby 
controlling the communication between 
cells and their environment (2). The activity 
of MMPs, ADAMTSs and ADAMs is 
physiologically regulated through formation 
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of a 1:1 stochiometric complex with their 
endogenous inhibitors called tissue 
inhibitors of metalloproteinases (TIMPs) (3), 
which comprise four members in mammals. 
Among them, TIMP-3 has a broader 
inhibitory profile, being unique in its ability 
to inhibit members of all three of these 
classes of metalloproteinases and regulate 
their activity in vivo (4). Timp3-null mouse 
displays a number of defects associated 
with excess of extracellular matrix (ECM) 
turnover, including signs of premature 
arthritis due to elevated activity of MMPs 
and ADAMTSs (4-6). Moreover, the Timp3-
null mouse releases high levels of TNFα 
upon challenge with surgical resection of 
the liver and other inflammatory models, 
due to excess ADAM17 activity (7). 
Decreased levels of TIMP-3 are present in 
degraded human osteoarthritis (OA) 
cartilage compared to normal cartilage. On 
the other hand, an increase in TIMP-3 
levels has been associated with protective 
inhibition of cartilage degradation in arthritis. 
For example, addition of TIMP-3 to 
cartilage explants has been shown to inhibit 
ADAMTS-mediated aggrecan degradation 
(8) and intra-articular injection of TIMP-3 
inhibited cartilage breakdown in a rat model 
of OA (9). For this reason, strategies to 
increase levels of TIMP-3 in the tissue have 
been widely sought as potential therapeutic 
treatment for arthritis and other conditions 
associated with deficit of the inhibitor. 
We previously discovered that 
extracellular levels of TIMP-3 are regulated 
by low-density-lipoprotein receptor-related 
protein-1 (LRP-1)-mediated endocytosis 
(10,11). As a consequence, no or little 
amount of TIMP-3 accumulates in the 
extracellular milieu unless its endocytosis is 
blocked (11). LRP-1 is a multidomain 
endocytic receptor that belongs to the LDL 
receptor family and is known to internalize 
more than 50 ligands through four ligand-
binding clusters (12). LRP-1 can undergo 
proteolytic shedding from the cell surface, 
with the subsequent release of a soluble 
form of the receptor (sLRP-1). We found 
that sLRP-1 competed with cell-surface 
LRP-1 for binding to TIMP-3 and increased 
its extracellular levels (10). Furthermore, 
when TIMP-3 is bound to sLRP-1, it retains 
its inhibitory activity against 
metalloproteinases, suggesting that 
shedding of LRP-1 and subsequent 
formation of sLRP-1/TIMP-3 complexes is a 
physiological mechanism to increase TIMP-
3 bioavailability in the extracellular milieu 
(10). 
In this study, we identified the major 
binding site for TIMP-3 on LRP-1 in the 
ligand-binding cluster II. Additionally, we 
found that a soluble minireceptor containing 
the N-terminal half of cluster II specifically 
binds to TIMP-3, but not its target 
metalloproteinases, and it selectively traps 
the inhibitor in the extracellular milieu. 
Unbiased shot-gun proteomics showed that 
this minireceptor, that we named T3TRAP, 
was able to inhibit constitutive shedding of 
a number of cell surface proteins, including 
the leukocyte surface antigen CD47, 
integrin beta-1 and cell adhesion molecule-
1. In conclusion, T3TRAP represents an 
effective biological tool to modulate TIMP-3 
levels in the extracellular space without 
affecting metalloproteinase turnover, 
thereby inhibiting proteolysis in the tissue. 
Potentially, it can prove beneficial in 
diseases characterized by deficit of TIMP-3, 
including cancer, arthritis and 
atherosclerosis. 
 
2. RESULTS 
 
2.1 Mapping of TIMP-3 binding sites on 
LRP-1 
LRP-1 is an endocytic receptor with a 
characteristic modular structure, with four 
ligand-binding clusters (LRPI-IV) driving the 
interaction between the receptor and its 
ligands. Each cluster contains sequences of 
2, 8, 10 and 11 cysteine-rich complement-
type repeats (CRs), respectively. All clusters 
comprise two EGF-like repeats at the C-
terminus, while domain II, III and IV also 
contain one EGF-like repeat at the N-
terminus (Figure 1A). To test which ligand-
binding cluster of LRP-1 interacts with 
TIMP-3, four soluble minireceptors 
containing the different ligand-binding 
clusters (sLRP1-4) were purified and their 
binding to TIMP-3 was measured by ELISA. 
TIMP-3 bound to sLRP2 with the greatest 
affinity, showing a KD,app of 7 nM (Figure 1B), 
similar to the affinity of TIMP-3 for full length 
LRP-1 in this assay (KD,app of 10 nM). TIMP-
3 bound to sLRP1, sLRP3 and sLRP4, but 
with lower affinity. 
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Figure 1. Binding of TIMP-3 to ligand-binding clusters of LRP-1. (A) Schematic 
representation of various sLRP minireceptors used in this study. (B) Full-length LRP-1 or 
recombinant LRP-1 ligand-binding clusters I (sLRP1), II (sLRP2), III (sLRP3) and IV (sLRP4) 
were coated onto microtiter plates and binding of TIMP-3-FLAG (0-100 nM) was measured 
using an M2 anti-FLAG antibody and a horseradish peroxidase-conjugated secondary 
antibody 
 
2.2 Development of a T3TRAP that 
increases extracellular bioavailability of 
TIMP-3.  
In order to develop a “trap” that 
would specifically increase extracellular 
levels of TIMP-3 (T3TRAP), we aimed to 
identify a fragment of LRP-1 that interacts 
with TIMP-3 and promotes its extracellular 
accumulation, without affecting the LRP-1-
mediated endocytosis of its target 
metalloproteinases. Having TIMP-3 shown 
the highest affinity for sLRP2 among the 
four binding domains, we investigated 
whether minireceptors consisting of the N-
terminal or C-terminal half of sLRP2 (termed 
sLRP2N and sLRP2C) were able to 
accumulate TIMP-3 in the medium of 
cutured U251 glioblastoma cells. Serial 
dilutions of conditioned media containing 
standardized amount of each minireceptor 
were added to U251 glioblastoma cells and 
TIMP-3 accumulation was evaluated. Figure 
2A and B shows that sLRP2N dose-
dependently increased accumulation of 
TIMP-3 in the conditioned media. A 
minireceptor consisting of sLRP2 without 
the EGF-like repeat (sLRP2N-E), was able 
to accumulate TIMP-3 in the medium to the 
same extent of sLRP2N, while the C-
terminal half of ligand-binding cluster II 
(sLRP2C) or sLRP2C without EGF-like 
repeats (sLRP2C-E) did not induce 
extracellular accumulation of the inhibitor. 
Together with previous results showing that 
TIMP-3 binds to sLRP2 with the highest 
affinity, these results indicate that the major 
TIMP-3 binding site resides on the N-
terminal moiety of LRP-1 binding cluster II, 
and that EGF-like repeats do not play a 
major role in this interaction. As a result, 
sLRP2N-E was considered as a possible 
T3TRAP and further investigated. We had 
sLRP4
sLRP3
sLRP2
sLRP1
Ligand-binding 
cluster I
Ligand-binding 
cluster IV
Ligand-binding 
cluster III
Ligand-binding 
cluster II
LRP-1 0 10 20 30 40 50
0.0
0.5
1.0
1.5 sLRP1
sLRP2
sLRP3
sLRP4
TIMP-3 (nM)
A
bs
or
ba
nc
e 
at
 4
50
 n
m
1 10 100 1000
0.0
0.5
1.0
1.5
TIMP-3 (nM)
A
bs
or
ba
nc
e 
at
 4
50
 n
m
LRP-1
A B
Complement-type  repeat EGF-like repeat β -propeller domain
sLRP2C
sLRP2N
sLRP2C-E
sLRP2N-E
 4	
previously shown that TIMP-3 endocytosis 
was inhibited when the protein is in complex 
with soluble LRP-1(10). Thus, we confirmed 
that the accumulation of TIMP-3 in the 
presence of sLRP2N-E was due to the 
inhibition of its endocytosis. Indeed, the 
endocytosis of TIMP-3 slows down when 
the inhibitor is in complex with sLRP2N-E 
(Figure 2C). Then, we tested the ability of 
sLRP2N-E to increase TIMP-3 in the 
extracellular milieu of cells other than U251. 
Similarly to U251 cells, the presence of 
sLRP2N-E induced a dose-dependent 
accumulation of TIMP-3 in the conditioned 
media of COS1 and PC3 cells (Figure 2D).
 
 
 
 
Figure 2. sLRP2N-E induces accumulation of TIMP-3 in conditioned media. (A) U251 
cells were incubated for 24 h with serial dilutions of conditioned media containing distinct 
sLRP minireceptors, conditioned media from mock transfected cells (ct) or conditioned 
media from mock transfected cells containing 200 µg/ml heparin (hep). The amount of TIMP-
3 accumulated in the extracellular space was analyzed by immunoblotting. (B) Bands 
corresponding to accumulated TIMP-3 were quantified using ImageJ and standardized with 
values of heparin for each blot (n=3). (C) FLAG-tagged TIMP-3 (5 nM) either alone or in the 
presence of sLRP2N-E was added to U251 cells. At indicated time points, the amount of 
TIMP-3-FLAG in the conditioned media was evaluated by immunoblotting using an anti-
FLAG M2 antibody. The intensity of bands corresponding to TIMP-3-FLAG at different times 
was quantified and plotted as percentage of values at 0 h (the experiment was performed 
twice with similar results). The solid line represents the average values of TIMP-3-FLAG in 
the presence of sLRP2N-E, while the dashed line represents the values of TIMP-3-FLAG 
alone. (D) TIMP-3 accumulation in the extracellular milieu of PC3 and COS1 cells was 
tested in the presence of serial dilutions of sLRP2N-E conditioned medium. 
 
 
 
 
 
 5	
 
 
Figure 3. sLRP2N-E is specific for TIMP-3, but not metalloproteinases. (A) Sensograms 
showing the binding of TIMP-3 (0-80 nM), midkine (140 nM), MMP-1 ∆C (600 nM), 
ADAMTS-5 (0-80 nM), MMP-2 (0-80 nM), MMP-9 (0-80 nM) or MMP-13 (0-80 nM) to 
sLRP2N-E. (B) Purified sLRP2N-E or full length LRP-1 were coated onto microtiter plates 
and binding of FLAG-tagged TIMP-3, ADAMTS5-2 or ADAMTS4-2 was evaluated by ELISA 
using an M2 anti-FLAG antibody. 
 
 
2.3 sLRP2N-E binds to TIMP-3, but not 
metalloproteinases  
A number of metalloproteinases 
have been identified as LRP-1 ligands (13-
16). Therefore, in order to understand the 
specificity of sLRP2N-E as a T3TRAP we 
investigated its interaction with these 
metalloproteinases by SPR. As showed by 
the sensograms in Figure 3A, TIMP-3 bound 
to sLRP2N-E at concentrations as low as 5 
nM. Midkine, that was previously shown to 
bind to the same fragment (17), efficiently 
bound to sLRP2N-E in this assay, while the 
catalytic domain of MMP-1 that has no 
affinity for the full-length receptor did not 
interact with sLRP2N-E at concentrations up 
to 640 nM. In the same assay, recombinant 
proMMP-2, proMMP-9, proMMP-13 and 
ADAMTS-5 displayed no affinity for 
sLRP2N-E (Figure 3A, Table 1). We also 
tested the selectivity of sLRP2N-E for TIMP-
3 by ELISA. While TIMP-3-FLAG efficiently 
bound to sLRP2N-E, neither FLAG-tagged 
ADAMTS-5 or ADAMTS-4 interacted with 
the minireceptor, even though their binding 
to full length LRP-1 was conserved in this 
assay (Figure 3B, Table 1). These data 
confirmed that sLRP2N-E is able to function 
as a selective T3TRAP (summarized in 
Table 1). 
 
 6	
 
Table 1. BINDING OF TIMP-3 AND METALLOPROTEINASES TO T3TRAP 
Binding of TIMP-3 and selected metalloproteinases to sLRP2N-E (T3TRAP), evaluated by 
different assays. 
 
Ligand Assay Binding 
   
TIMP-3 SPR/ELISA 
 
Positive binding in the nanomolar range 
ProMMP-2 SPR No binding up to 80 nM 
proMMP-9 SPR No binding up to 80 nM 
proMMP-13 SPR No binding up to 80 nM 
ADAMTS-5 SPR No binding up to 80 nM 
ADAMTS5-2 ELISA No binding up to 50 nM 
ADAMTS4-2 ELISA No binding up to 600 nM 
 
 
2.4 T3TRAP increases TIMP-3 levels in 
the conditioned medium and inhibits 
protein shedding 
LRP-1 is known to internalize more 
than 50 ligands, therefore we investigated 
which proteins, other than TIMP-3, could be 
upregulated in the extracellular milieu in the 
presence of T3TRAP. We performed a 
mass spectrometry-based secretome 
analysis of HEK293 cells expressing 
T3TRAP. This analysis identified 341 
secreted proteins and 168 membrane 
proteins in the conditioned media of both 
controls and T3TRAP expressing cells 
(Uniprot annotation). T3TRAP was only 
detected in transfected cells (average LFQ 
value 1,58E+08, Table S1). The large 
majority of proteins detected in the 
secretome were not regulated by the 
overexpression of T3TRAP (Figure 4A, 
Table S1). TIMP-3 levels increased 4.3-fold 
in the presence of T3TRAP, with the highest 
degree of statistical significance among all 
the proteins regulated (Figure 4A and 4B, 
Table 2). Similarly to TIMP-3, the Chitinase 
domain-containing protein 1 (CHID1) was 
found upregulated by the presence of 
T3TRAP (8.7-fold). Other proteins, including 
collagen a1(XIV) chain, peroxiredoxin-4, 
laminin subunit b2 and cholinesterase, were 
found to be upregulated in the secretome of 
T3TRAP cells, but with lower relevance 
compared to TIMP-3 (Figure 4A, Table 2). 
Midkine, whose endocytosis had been 
previously found to be inhibited by sLRP2N-
E, slightly accumulated in the conditioned 
media of T3TRAP-expressing cells (1.2-fold, 
p-value: 0.0027; Table S1) (17). 
Some metalloproteinases were 
detected in the secretome of T3TRAP 
expressing cells, including ADAMTS-1, 
ADAMTS-3 and MMP-11, but they were not 
significantly regulated by the presence of 
the trap. Similarly, TIMP-1 and TIMP-2, 
were not regulated by the expression of 
T3TRAP (Figure 4A and 4B). Interestingly, 
levels of MMP-2, which is known to be an 
LRP-1 ligand, were decreased in T3TRAP 
expressing cells (Figure 4A, Table 2). 
Similarly to MMP-2, other proteins including 
insulin-like growth factor II, apolipoprotein E, 
transforming growth factor beta-1 and agrin, 
were downregulated in the presence of 
T3TRAP. 
A number of membrane-anchored 
proteins that are known to be shed by 
metalloproteinases, including leukocyte 
surface antigen CD47 (18), integrin beta-1 
(19), cell adhesion molecule 1 (20) and 
CD166 antigen (21), were significantly 
reduced in the secretome of T3TRAP 
expressing cells, suggesting that T3TRAP, 
and subsequent increased levels of TIMP-3, 
overall inhibited the constitutive 
metalloproteinase-dependent shedding of 
membrane proteins (Table 2).  
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Figure 4. sLRP2N-E selectively increases TIMP-3 extracellularly. (A) Volcano plot 
showing P values (-log10) versus protein ratio of sLRP2N-E (T3TRAP)-expressing/mock-
transfected cells (log2) of 514 secreted and membrane-type proteins (n=6). The horizontal 
dashed line indicates the –log10(P value) of 1.3 (threshold for statistical significance). The 
two solid lines (hyperbolas) represent the permutation-based false-discovery rate (FDR) 
analysis used to evaluate the statistical significance of protein regulation in the two 
conditions (T3TRAP and controls). Proteins above the hyperbolas are considered 
statistically significant according to the permutation-based FDR (250 randomizations, FDR: 
0.05, SO: 0.1). (B) Validation of secretome analysis: immunoblots showing the expression of 
sLRP2N-E (T3TRAP) in the conditioned media of transfected cells, and the subsequent 
increase in TIMP-3 levels compared to mock-transfected controls. TIMP-1, TIMP-2 and 
sAPP were detected as proteins non-regulated by T3TRAP expression by the proteomic 
analysis and validated by Western blots.  
 
 
3. DISCUSSION  
TIMP-3 is a major regulator of ECM 
turnover and TIMP-3-mediated inhibition of 
metalloproteinases has been shown to have 
a protective role in different diseases, 
including cancer, atherosclerosis and 
arthritis (9,22,23). For this reason there has 
been considerable interest in understanding 
the mechanisms controlling TIMP-3 levels in 
the tissue. We have previously reported that 
extracellular levels of TIMP-3 can be 
modulated by LRP-1-mediated endocytosis, 
which is prevented when the inhibitor is 
bound to a shed form of LRP-1 or to low 
molecular weight fragments of the receptor 
(10). Studies on chondrosarcoma cells and 
macrophages have shown that ectopic 
overexpression of Timp3 does not lead to 
an increase of extracellular levels of the 
inhibitor, unless its endocytosis is blocked 
(11,23). Therefore, shedding of LRP-1 and 
formation of TIMP-3/sLRP-1 complexes 
seem to be a major mechanism for 
regulating the bioavailability of TIMP-3 in the 
tissue. This study aimed to develop a 
T3TRAP that mimics shed LRP-1 in 
preventing TIMP-3 from being internalized 
thereby increasing its levels in the tissue. 
Therefore, we investigated the LRP-1-TIMP-
3 interaction in detail in order to find the 
binding site for TIMP-3 on the receptor and 
develop a molecule that selectively 
increases extracellular levels of TIMP-3. 
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Table 2. CHANGES IN PROTEIN SECRETION IN T3TRAP EXPRESSING CELLS 
 
 
Soluble proteins increasing in the conditioned medium of T3TRAP expressing cells 
 
Protein name Gene IDa Ratiob p-value pept 
      
Metalloproteinase inhibitor 3 TIMP3 
 
P35625 4.35 1.76E-09 
 
17 
Chitinase domain-containing protein 1 CHID1 Q9BWS
9 
8.70 9.21E-09 20 
Collagen alpha-1(XIV) chain COL14A1 Q05707 5.65 1.36E-04 10 
Peroxiredoxin-4 PRDX4 Q13162 2.97 6.47E-05 25 
Laminin subunit beta-2 LAMB2 P55268 2.21 6.10E-04 21 
Cholinesterase BCHE P06276 2.03 1.79E-05 5 
 
  Soluble proteins decreasing in the conditioned medium of T3TRAP expressing cells 
 
Protein name Gene ID Ratio p-value pept 
      
Insulin-like growth factor II IGF2 P01344 0.52 1.33E-02 5 
Apolipoprotein E APOE P02649 0.56 2.40E-03 13 
72 kDa type IV collagenase MMP2 P08253 0.63 4.69E-04 9 
Transforming growth factor beta-1 TGFB1 P01137 0.67 1.10E-02 8 
Agrin AGRN O00468 0.68 1.70E-04 29 
 
Selection of proteins unaltered in T3TRAP expressing cells 
 
Protein name Gene ID Ratio p-value pept 
      
A disintegrin and metalloproteinase with 
thrombospondin motifs 1 
ADAMTS1 Q9UHI8 0.99 9.14E-01 30 
Metalloproteinase inhibitor 1 TIMP1 P01033 0.90 8.05E-02 12 
Metalloproteinase inhibitor 2 TIMP2 P16035 0.87 2.78E-01 14 
SPARC SPARC P09486 1.07 3.97E-01 14 
Glia-derived nexin SERPINE2 P07093 1.06 7.55E-01 14 
Serin protease 23 PRSS23 O95084 1.10 4.20E-01 11 
Amyloid precursor protein  APP P05067 0.98 7.97E-01 28 
 
Membrane proteins showing reduced shedding in T3TRAP expressing cells 
 
Protein name Gene ID Ratio p-value pept 
      
Leukocyte surface antigen CD47 CD47 Q08722 0.70 1.39E-03 3 
Integrin beta-1 ITGB1 P05556 0.71 2.06E-03 15 
Cell adhesion molecule 1 CADM1 Q9BY67 0.71 6.28E-03 8 
CD166 antigen ALCAM Q13740 0.77 2.34E-03 16 
Cell surface glycoprotein MUC18 MCAM P43121 0.77 2.06E-04 11 
 
ID: accession number of the protein 
Ratio: mean ratio of label-free quantification intensities between T3TRAP-expressing and 
control conditions (n=6) 
p-value: for six biological replicates 
pept: number of identified peptides of the protein group 
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A canonical mode of ligand 
recognition by LRP-1 underlies a central 
role for the cysteine-rich complement-type 
repeats (CRs). These cage-shaped CRs 
present a characteristic acidic pocket that 
forms salt bridges with a specific lysine on 
the ligand moiety, as it was shown for a 
number of LRP-1 ligands (24,25). Five 
lysine residues, Lys-26, Lys-27, Lys-30, 
Lys-76 and Lys-165, are located on the 
opposite side of the inhibitory ridge of TIMP- 
3 that may be involved in LRP-1 recognition 
(10). The presence of multiple lysines 
available for LRP-1 recognition may explain 
the high affinity of TIMP-3 for LRP-1, with a 
KD,app in the low nanomolar range, and also 
the presence of multiple binding sites for 
TIMP-3 on the receptor. Indeed, the inhibitor 
efficiently bound all four LRP-1 ligand-
binding clusters, with highest affinity for 
cluster II. The major binding site for TIMP-3 
was identified on the N-terminal half of this 
cluster, but the affinity of the inhibitor for this 
fragment alone was clearly reduced 
compared to that for the whole cluster II. We 
speculate that the majority of the 
interactions between TIMP-3 and LRP-1 are 
mediated by crucial lysines on the inhibitor 
moiety and CRs on the N-terminal half of 
cluster II, with additional interactions 
between TIMP-3 and the C-terminal half that 
stabilize the binding, thus increasing its 
affinity. 
LRP-1 is currently known to bind 
over 50 ligands, including a number of 
TIMP-3 target metalloproteinases (i.e. MMP-
2, MMP-9, MMP-13, ADAMTS-4 and 
ADAMTS-5) (13-16). Interestingly, none of 
these metalloproteinases was able to 
interact with the N-terminal half of cluster II. 
This suggests two possibilities: either the 
binding site for TIMP-3 is physically 
separated from the binding site of its target 
metalloproteinases or metalloproteinases 
require both N-terminal and C-terminal 
moieties to interact with LRP-1. A 
secretome analysis of cells expressing a 
soluble form of the C-terminal half of cluster 
II did not identify upregulation of 
metalloproteinases in the conditioned media 
(not shown), suggesting that both N-and C-
terminal halves are required to mediate the 
interaction between LRP-1 and 
metalloproteinases. The differential binding 
of LRP-1 ligands to diverse domains of the 
receptor may have important physiological 
consequences. Indeed, different fragments 
of shed LRP-1 has been found in cancer 
cells, human brains and cerebrospinal fluids 
(26,27). Similar fragments were also found 
associated with extracellular TIMP-3 and 
shown to inhibit its endocytosis (10). It is 
interesting to speculate that differential 
cleavage of LRP-1 can lead to the release 
of different LRP-1 fragments, thereby 
specifically preventing the internalization of 
some proteins (or group of proteins) but not 
others, thus leading to different biological 
responses. Determining the precise nature 
of these fragments may lead to a better 
understanding of LRP-1 role in ECM 
turnover, indeed differential cleavage of the 
receptor can be crucial to regulate the 
catabolism/anabolism equilibrium of the 
ECM.  
In conclusion, metalloproteinases 
are known to play important roles in a 
number of physiological and pathological 
processes. For its ability to increase tissue 
levels of TIMP-3, without affecting the 
turnover of its target metalloproteinases, 
T3TRAP can potentially be used to 
investigate the role of TIMP-3 in these 
processes and exploited in the therapy of 
diseases characterized by enhanced ECM 
proteolysis, including arthritis. 
 
4. EXPERIMENTAL PROCEDURES 
4.1 Proteins 
Human recombinant proMMP-2, 
proMMP-9, proMMP-13 and ADAMTS-5 
were purchased from R&D Systems. BSA 
was from Sigma-Aldrich. Human midkine 
from Peptide Institute Inc. The catalytic 
domain of human MMP-1 (MMP-1ΔC) (28), 
C-terminally FLAG-tagged ADAMTS-4 
lacking the C-terminal spacer domain, 
named ADAMTS4-2 (16), C-terminally 
FLAG-tagged ADAMTS-5 lacking the C-
terminal thrombospondin domain, named 
ADAMTS5-2, (16), and C-terminally FLAG-
tagged TIMP-3 (29) were generated as 
previously described. Human LRP-1 
isolated from placenta was purchased from 
BioMac. His-tagged soluble ligand-binding 
domains of LRP-1 (sLRP1, sLRP2, sLRP3 
and sLRP4) were purified as previously 
described (16). Briefly, each LRP-1 ligand-
binding cluster (sLRP1-4) was transiently 
expressed in HEK293 cells using TransIT-
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2020 transfection reagent (Mirus). 
Conditioned media were collected after 72 h 
and directly applied to a nickel-nitrilotriacetic 
acid affinity column (Qiagen). Proteins were 
then eluted by 500 mM imidazole in HEPES 
(pH 7.5) buffer containing 150 mM NaCl and 
5 mM CaCl2.  
 
4.2 Purification of sLRP2N-E-Fc 
(T3TRAP) 
The construct for expressing 
sLRP2N-E-Fc (T3TRAP) was generated as 
previously described (30). Briefly, the 
sequence of human LRP1 corresponding to 
the amino acid region 826–994 was cloned 
into pFUSE-Fc (Invitrogen). HEK293 cells 
were transfected with the construct and after 
5 days the conditioned medium was 
collected and applied onto a protein G-
Sepharose column (GE Healthcare). After 
washing with 30 ml of PBS, the bound 
fraction was eluted with 3.6 ml of 100 mM 
glycine HCl (pH 3.0) and neutralized 
immediately with 0.4 ml of 1.5 M Tris-HCl 
(pH 8.8). Purity of the protein was confirmed 
by SDS-PAGE analysis and subsequent 
silver staining. 
 
4.3 ELISA for binding of FLAG-tagged 
TIMP-3, ADAMTS5-2 and ADAMTS4-2 to 
LRP-1, sLRPs or sLRP2N-E 
Full-length LRP-1, purified ligand-
binding domains (sLRP1-4) or sLRP2N-E 
were coated onto an ELISA plate (overnight, 
4° C). Wells were blocked with 3% BSA in 
TNC buffer [(50 mM Tris-HCl, 150 mM NaCl, 
5 mM CaCl2, pH 7.4) (1 h, 37 °C)] and 
washed in TNC buffer containing 0.05% 
(v/v) Brij-35 after this and each subsequent 
step. Wells were then incubated with 
various concentrations of FLAG-tagged 
TIMP-3, ADAMTS4-2 or ADAMTS5-2 in 
blocking solution [3 h, room temperature 
(RT)]. Bound protein was detected using 
anti-FLAG M2 mouse monoclonal antibody 
(1 h, RT) and then with an anti-mouse IgG 
antibody coupled to horseradish peroxidase 
(Abcam; 1 h, RT). Hydrolysis of 
tetramethylbenzidine substrate (KPL) was 
measured at 450 nm in a plate reader. Each 
value was normalized by subtracting the 
amount of ligand bound to control wells that 
were not coated with LRP-1 or soluble LRP-
1 fragments. 
 
4.4 Analysis of TIMP-3 accumulation in 
the conditioned media 
HA_tagged minireceptors comprising 
parts of the ligand-binding cluster II 
(sLRP2N, sLRP2C, sLRP2N-E and 
sLRP2C-E, illustrated in Figure 1A) were 
generated as previously described (17,30). 
HEK293 cells were transiently transfected 
with each construct using Fugene HD 
transfection reagent (Promega) and the 
conditioned media were collected 5 days 
after transfection. In order to standardize 
levels of distinct minireceptors in each 
conditioned media, their expression was 
evaluated by Western blot analysis using an 
anti-HA antibody (Roche) and subsequent 
band quantification using ImageJ software.  
Conditioned media containing standardized 
amount of each minireceptor were 
incubated with a number of different cell 
lines (including U251 human glioblastoma, 
PC3 prostate adenocarcinoma and COS1) 
for 24 h, and accumulation of TIMP-3 in the 
conditioned media was evaluated by 
immunoblotting using a polyclonal anti-
TIMP-3 antibody (Millipore). No TIMP-3 was 
detected by Western blot in the 
minireceptor-containing conditioned media 
before incubation with cell lines. Negative 
controls were incubated with conditioned 
media collected from cells transfected with 
an empty vector (pcDNA3.1, Invitrogen). 
Positive controls were incubated in 
conditioned medium from mock transfected 
cells, supplemented with 200 µg/ml heparin 
that blocks TIMP-3 endocytosis (10,11). 
Pixel density of the bands corresponding to 
TIMP-3 was quantified using ImageJ and 
displayed as a percentage of the values 
corresponding to TIMP-3 bands in the 
heparin-treated samples (positive controls).  
 
4.5 Analysis of TIMP-3 endocytosis 
Purified TIMP-3-FLAG (5 nM) was 
incubated with an equimolar concentration 
of purified sLRP2N-E for 1 h at 37 °C, in 
order to form TIMP-3/sLRP2N-E complexes 
in DMEM with 0.1 % of serum. Then, 
complexes were added onto U251 cells and 
conditioned media collected at different time 
points. TIMP-3-FLAG in the conditioned 
media was detected by Western blotting, 
using an anti-FLAG M2 antibody. Amount of 
TIMP-3-FLAG in different samples was 
determined by band quantification and 
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plotted as a percentage of values 
corresponding to the amount of TIMP-3 at 0 
h.  
 
4.6 Analysis of TIMP-3 and 
metalloproteinase binding to sLRP2N-E 
by surface plasmon resonance (SPR) 
The binding of TIMP-3 and 
metalloproteinases to the sLRP2N-E was 
analyzed by Biacore 3000. Purified 
sLRP2N-E was immobilized on a CM5 
sensor chip by amine coupling using N-
hydroxysuccinimide (NHS). Recombinant 
TIMP-3, midkine, proMMP-2, proMMP-9 and 
proMMP-13 and ADAMTS-5 were injected 
over the immobilized sLRP2N-E at eight 
concentrations ranging from 0 to 80 nM, 
unless differently specified. Each 
experiment was performed in triplicate.  
 
4.7 Proteomic analysis of conditioned 
media from T3-TRAP expressing HEK 
cells 
HEK cells were cultured in 6-well 
plates and transfected with sLRP2N-E or 
empty vector in serum-free DMEM. After 24 
h, supernatants were harvested and 
centrifuged to remove cell debris. Protein 
concentration in supernatants was 
measured using the colorimetric 660 nm 
assay (Thermo Fisher Scientific, US). A 
protein amount of 25 µg per sample was 
subjected to proteolytic digestion using the 
filter assisted sample preparation (FASP) 
protocol with 10 kDa Vivacon spin filters 
(Sartorius, Germany) (31). Briefly, proteins 
were denatured with 8M urea in 100 mM 
TRIS/HCl pH 8.5, followed by reduction with 
100 mM dithiotreitol for 30 min and 
subsequent alkylation with 50 mM 
iodoacetamide for 30 min in the dark. 
Proteins were digested with 0.5 µg LysC 
(Promega) over night and subsequently with 
0.5 µg trypsin (Promega) for 4 h at 37º C. 
Peptides were desalted on reversed phase 
C18 StageTips, and eluted using 40 µl of 
60% acetonitrile in 0.1% formic acid. The 
volume was reduced in a SpeedVac and the 
peptides were resuspended in 0.1% formic 
acid. Proteolytic peptides were desalted by 
stop and go extraction (STAGE) with C18 
tips (32). The purified peptides were dried 
by vacuum centrifugation. Samples were 
dissolved in 40 µL 0.1% formic acid and 
analyzed by LC-MS/MS.  
A number of proteins detected in the 
analysis were further validated by 
immunoblotting (T3TRAP, TIMP-3, TIMP-1, 
TIMP-2, sAPP). 
 
4.8 Proeteomic data analysis 
The data was analyzed by the 
software Maxquant (maxquant.org, Max-
PlanckInstitute Munich) version 1.5.2.8. The 
MS data was searched against a reviewed 
canonical fasta database of Homo sapiens 
from UniProt (download: December 12th 
2014, 16685 entries). Trypsin was defined 
as protease. Two missed cleavages were 
allowed for the database search. The option 
first search was used to recalibrate the 
peptide masses within a window of 20 ppm. 
For the main search peptide and peptide 
fragment mass tolerances were set to 4.5 
and 20 ppm, respectively. 
Carbamidomethylation of cysteine was 
defined as static modification. Acetylation of 
the protein N-term as well as oxidation of 
methionine was set as variable 
modifications. The false discovery rate for 
both peptides and proteins was adjusted to 
less than 1%. Label free quantification 
(LFQ) of proteins required at least two ratio 
counts of unique peptides. Only unique 
peptides were used for quantification. The 
LFQ values were log2 transformed and a 
two sided heteroscedastic student’s ttest 
was used to evaluate statistically significant 
regulated proteins between mocktransfected 
and T3TRAP-expressing HEK293 cells. A P 
value less than 5% was set as significance 
threshold. Permutation-based false-
discovery rate (FDR) analysis was used to 
evaluate the statistical significance of 
protein regulation in the two conditions (250 
randomizations, FDR: 0.05, SO: 0.1).  
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